好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Vitamin D3 and Diabetic Neuropathy - Analysis of EMG/NCS Parameters
Clinical Neurophysiology
S59 - (-)
003
Vitamin D3 (VitD3) deficiency has been implicated in a variety of neurological diseases. It has also been linked to the development of insulin resistance by causing low grade inflammation. VitD3 supplements reduce neuropathic pain in diabetic patients. VitD3 deficiency has been associated with development of diabetic neuropathy.
The study was performed as a retrospective chart review at the Veterans Association Hospital in Buffalo, NY. Patients who have diabetic neuropathy, have serum VitD3 levels and who have had EMG/NCS were identified and their results was reviewed. The patients were divided into two categories (VitD3 deficient and normal) and the CMAP amplitudes, conduction velocities, F-latencies, sural SNAP latencies/amplitudes were compared using independent T-tests. The percentage of patients with conduction block were calculated in each group and analyzed with chi-sq. Linear correlation model/graphs were plotted to analyze the relationship between serum levels of deseasonalized VitD3 with the parameters.
The study showed that tibial conduction velocity and median CMAP amplitude were significantly worse in the Vitamin D3 deficient group. Conduction block was present 3.6 to 6.6 times higher in patients with vitamin D3 deficiency. VitD3 deficient diabetic neuropathy patients were 3.1 times more likely to have an absent sural nerve response compared to diabetics with normal VitD3 level. Vitamin D3 levels showed inverse correlation with HbA1c levels, tibial and ulnar CMAP amplitudes.
Compared to diabetics with normal Vitamin D3 levels, the patients with VitD3 deficiency were more likely to have conduction block and absent sural sensory nerve responses. Tibial and median nerve conduction parameters were worse in patients with Vitamin D3 deficiency.
Authors/Disclosures
Anil Neelakantan, MD, FAAN
PRESENTER 		Dr. Neelakantan has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Gould Medical Group.
Nicholas J. Silvestri, MD, FAAN (UBMD Neurology) Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of an immediate family member of Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Silvestri has received publishing royalties from a publication relating to health care.
Dieter Haering Dieter Haering has received personal compensation for serving as an employee of Novartis.